Akebia Therapeutics (AKBA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 236,196 | 160,180 | 194,623 | 292,484 | 211,650 |
| Cost of Goods | 39,462 | 63,177 | 74,149 | 85,568 | 150,671 |
| Gross Profit | 196,734 | 97,003 | 120,474 | 206,916 | 60,979 |
| Operating Expenses | 173,697 | 147,652 | 166,879 | 288,263 | 326,152 |
| Operating Income | 23,499 | -50,472 | -46,256 | -80,779 | -264,502 |
| Interest Expense | 24,179 | 18,185 | 6,032 | 15,687 | 19,936 |
| Other Income | -3,041 | -753 | 363 | 2,240 | 2,414 |
| Pre-tax Income | -3,721 | -69,410 | -51,925 | -94,226 | -282,024 |
| Income Tax | 1,624 | N/A | N/A | N/A | N/A |
| Net Income Continuous | -5,345 | -69,410 | -51,925 | -94,226 | -282,024 |
| Net Income | $-5,345 | $-69,410 | $-51,925 | $-94,226 | $-282,024 |
| EPS Basic Total Ops | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
| EPS Basic Continuous Ops | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
| EPS Diluted Total Ops | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
| EPS Diluted Continuous Ops | -0.02 | -0.33 | -0.28 | -0.52 | -1.70 |
| EPS Diluted Before Non-Recurring Items | -0.02 | -0.33 | -0.28 | -0.43 | -1.70 |
| EBITDA(a) | $24,768 | $-12,968 | $-8,629 | $-43,082 | $-226,547 |